The impact of COVID-19 on ischemic stroke: A case report

doi:10.21203/rs.3.rs-20393/v1

Download PDF

Case Report

The impact of COVID-19 on ischemic stroke: A case report

https://doi.org/10.21203/rs.3.rs-20393/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Background

The outbreak of a novel coronavirus since December 2019 in Wuhan, became an emergency of major international concern. As of March 5, 2020, the SARS-CoV-2 epidemic has caused 80,565 confirmed infections with 3,015 fatal cases in China. The SARS-CoV-2 outbreak is a major challenge for clinicians. In our clinic, we found a rare case that a COVID-19 patient combined with ischemic stroke.

Case Presentation

A 79-year-old man was admitted to the Hubei Provincial Hospital of Chinese Traditional Medicine due to right limb weakness for 1 day and slight cough for 1 week. At presentation, his body temperature was 37.3°C (99.0°F) with some moist rales. Neurological examination showed right limb weakness, and the limb muscle strength was grade 4. The left leg and arms were unaffected. In addition, runs of speech were not fluent enough with tongue deviation. Laboratory studies showed lymphopenia and eosinophilic granulocytopenia. Chest CT revealed bilateral pulmonary parenchymal ground-glass and consolidative pulmonary opacities, with a peripheral lung distribution. Real-time polymerase chain reaction (RT-PCR) from throat swab sample was positive for SARS-CoV-2 nucleic acid. This patient was treated with antiviral drugs and anti-inflammatory drugs with supportive care until his discharge. Clopidogrel (75 mg) and atorvastatin (20 mg) were administered orally to treat acute ischemic stroke. After twelve days of treatment, he can walk normally and communicate with near fluent language.

Conclusion

We report an even more unusual case, a patient who was hospitalized for right limb weakness and was later diagnosed with COVID-19. Here, SARS-CoV-2 infection caused hypoxemia and excessive secretion of inflammatory cytokines, which contribute to the occurrence and development of ischemic stroke. Once COVID-19 patients show acute ischemic stroke, neurologists should cooperate with infectious disease doctors to help patients.

Infectious Diseases

COVID-19

SARS-CoV-2

Ischemic stroke

Hypoxemia

Case report

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously termed 2019 novel coronavirus or 2019-nCoV) disease in China at the end of 2019 has caused a large global outbreak and became a major public health issue. As of March 5, 2020, data from the World Health Organization (WHO) have shown that there is now a total of 95,265 reported cases of COVID-19 in 33 countries/regions, and 3281 deaths. It is spread by human-to-human transmission via direct contact or aerosols [1]. The SARS-CoV-2 infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality [2]. Among patients with pneumonia caused by SARS-CoV-2, fever was the most common symptom, followed by cough [3]. Bilateral lung involvement with ground-glass opacity was the most common finding from computed tomography images of the chest [4]. Lymphopenia is a common feature in the patients with COVID-19 and might be a critical factor associated with disease severity and mortality [5].

The complications of COVID-19 included acute respiratory distress syndrome (29%), aemia (15%), acute cardiac injury (12%) and secondary infection (10%) [2]. 26.1% COVID-19 patients were transferred to the intensive care unit (ICU) because of complications [6]. In the course of clinical treatment of COVID-19, we found an interesting case that COVID-19 was followed by the onset of ischemic stroke, even though pneumonia is a frequent complication after stroke associated [7]. In this case report, we depicted a 79-year-old man who was hospitalized for right limb weakness and was later diagnosed with COVID-19. The relative roles of aging, oxidative stress, endothelial dysfunction, inflammation status, and other vascular risk factors could contribute to stroke [8, 9]. Hypoxemia and inflammation induced by COVID-19 may contribute to the occurrence, development and prognosis of ischemic stroke. This usual case suggests that neurologists should be vigilant in regards to COVID-19, especially those whose initial symptoms are neurological symptoms, and take effective measures of protection.

On January 24, 2020, a 79-year-old man was admitted to the Hubei Provincial Hospital of Chinese Traditional Medicine (Guanggu, Wuhan, Hubei Province) due to right limb weakness for 1 day and slight cough for 1 week. At presentation, his body temperature was 37.3°C (99.0°F) with some moist rales. On January 7, 2020, he attended a large banquet and visited his friends. At administration, a neurological examination showed right limb weakness, and the limb muscle strength was grade 4. The left leg and arms were unaffected. In addition, runs of speech were not fluent enough with tongue deviation. The patient did not have nystagmus, oculomotor deficit, or sensory abnormality of the face, and the rest of the cranial nerve examination was normal. Deep tendon reflexes were symmetrically normal, cutaneous plantar response was flexor on both sides, and touch and vibration sense were normal. Medical, family, and psycho-social history were normal. The general examination indicated that the patient had hypertension (blood pressure: 165/120 mm Hg). Brain CT showed lacunar infarction. Forty-eight-hour Holter monitoring found paroxysmal atrial fibrillation.

Laboratory studies showed lymphopenia (lymphocyte cell count, 0.71 × 10⁹/L) and eosinophilic granulocytopenia (eosinophilic cell count, 0.002 × 10⁹/L). The leukopenia cell count (white blood cell count, 7.08× 10⁹/L) was normal. The white blood cell differential count displayed 86.1% neutrophils (normal range, 20.0%-50.0%), 6.0% lymphocytes (normal range, 40.0%-75.0%), and 7.7% monocytes (normal range, 3.0%-10.0%). Several additional laboratory tests were abnormal, including C-reactive protein (36.1 mg/L; normal range, 0-10 mg/L), erythrocyte sedimentation rate (43 mm/h; normal range, <20 mm/h), high density lipoprotein (1.04 mmol/L; normal range, 1.16-1.42 mmol/L), lipoprotein(a) (1276 mg/L; normal range, 10-300 mg/L), oxygen saturation (94.2%) on room air, and blood sugar (7.9 mmol/l; normal range, 3.9-6.1 mmol/l). The laboratory test results for cardiac, renal, and coagulation functions were normal. Since this patient noted having a slight cough, respiratory pathogens, including influenza virus, mycoplasma pneumoniae, adenovirus, coxsackievirus, and cytomegalovirus were checked, and these results were negative. Chest CT was performed at the same time, revealing bilateral pulmonary parenchymal ground-glass and consolidative pulmonary opacities, with a peripheral lung distribution (Figure 1A). Real-time polymerase chain reaction from a throat swab sample was positive for SARS-CoV-2 nucleic acid.

This patient was treated with antiviral drugs (oseltamivir, 75 mg, bid; ribavirin, 0.5 g, bid) and anti-inflammatory drugs (moxifloxacin, 0.4 g/day) with supportive care until his discharge on February 4, 2020. We prescribed five doses of dexamethasone (10 mg/day) until interim guidance from the WHO was released. Clopidogrel (75 mg) and atorvastatin (20 mg) were administered orally to treat acute ischemic stroke. Amlodipine besylate tablets were given to lower the patient’s blood pressure. Adverse and unanticipated events were not observed. After twelve days of treatment, he can walk normally and communicate with near fluent language. The respiratory symptoms of cough disappeared. Serial CT images illustrate the patient’s improvement after therapy (Figure 1B).

The interest of the present case is 2-fold: (1) it is the first description of COVID-19 with right limb weakness as the initial symptom; and (2) it shows that COVID-19 is one of the pathogeneses of ischemic stroke.

The outbreak of a novel coronavirus since December 12, 2019 in Wuhan, the major transportation Hubei in Central China, became an emergency of major international concern. As of March 5, 2020, the SARS-CoV-2 epidemic has caused 80,565 confirmed infections with 3,015 fatal cases in China. The SARS-CoV-2 outbreak is a major challenge for clinicians. The typical symptoms are fever, sore throat, fatigue, cough or dyspnea coupled with recent exposure. The SARS-CoV-2 infection is of clustering onset, which is more likely to affect older males with comorbidities [10]. The elderly always have higher risk factors associated with acute ischemic stroke or embolization vascular events. Considering that this patient is 79 years old and the immune response is not as strong as that in young men, typical symptoms of SARS-CoV-2 infection were not observed. After he visited friends, ten days later, he began to cough slightly. The mean incubation period of COVID-19 is 6.4 days, ranging from 2.1 to 11.1 days (2.5th to 97.5th percentile) [11]. We suspect that he was exposed to the viral environment, in which some aerosols may carry SARS-CoV-2. This patient was hospitalized with right limb weakness and disfluent speech, and chest CT examination later found typical images of COVID-19, suggesting that neurologists ought to inquire more information about the contact history. In addition, chest CT and laboratory examinations, including swab tests, should be prescribed for the diagnosis of COVID-19.

In this case, to explain right limb weakness as the initial symptom, it has been hypothesized that SARS-CoV-2 infection caused hypoxemia and excessive secretion of inflammatory cytokines, which induced acute ischemic stroke. Hypoxemia significantly reduces the energy required by cell metabolism, increases anaerobic fermentation, and causes intracellular acidosis and oxygen free radicals. With the continuation of hypoxia, intracellular calcium ion concentration increases significantly, inducing a series of cell damage, including apoptosis. Moreover, hypoxia can also induce inflammatory responses, including inflammatory cell infiltration and cytokine release, leading to further tissue ischemia [12]. Inflammation plays an important role in the occurrence, development and prognosis of cardiovascular and cerebrovascular diseases. Compared with non-ICU patients, ICU patients with a SARS-CoV-2 infection had higher plasma cytokine levels, including IL-2, IL-7, IL-10, GSCF, IP10, MCP1, MIP1A, and TNFα [2]. Inflammation contributes to atherosclerosis and affects plaque stability [13]. Following this idea, we presume that SARS-CoV-2 infection pneumonia is one of the pathogeneses of ischemic stroke. The latest full-length genome sequences obtained revealed that SARS-CoV-2 uses the cell entry receptor ACE2 [14]. Structural analysis suggests that ACE2 can bind to B⁰AT1 (SLC6A19), which is a neutral amino acid transporter, providing important clues to the molecular basis for coronavirus recognition and infection [15]. Due to the combination of SARS-CoV-2 with the ACE2 receptor, some hypertensive patients with SARS-CoV-2 infection may experience abnormally elevated blood pressure, which increases the risk of intracerebral hemorrhage. In a familial cluster of pneumonia associated with SARS-CoV-2, older patients (aged >60 years) have more systemic symptoms, such as thrombocytopenia, which enhances the chances of acute cerebrovascular events [16]. In the clinic, some COVID-19 patients have intracranial infection symptoms, including headache, epilepsy, and consciousness disorders; some COVID-19 patients have acute cerebrovascular disease symptoms, including paralysis of limbs; and a few have neuralgia and paresthesia.

Early diagnosis, quarantine, and supportive treatments are essential to cure patients. As SARS-CoV-2 is an emerging virus, no antiviral agents have been recommended for coronavirus infection [17]. In this case, low doses of dexamethasone therapy were used to avoid inflammatory storms. Corticosteroids suppress lung inflammation but also inhibit immune responses and pathogen clearance. The clinical outcomes of coronavirus and similar outbreaks do not support the use of corticosteroids [18-20]. Current interim guidance from the WHO on the clinical management of severe acute respiratory infection when SARS-CoV-2 infection is suspected (released January 28, 2020) advises against the use of corticosteroids unless indicated for another reason.

We report an even more unusual case, a patient who was hospitalized for right limb weakness combined with poor speech fluency and was later diagnosed with COVID-19.
During the period of the outbreak of COVID-19, neurologists should be vigilant in regards to COVID-19, especially those whose initial symptoms are neurological symptoms, and take effective measures of protection.
COVID-19 may contribute to the occurrence, development and prognosis of ischemic stroke.
Once COVID-19 patients show acute ischemic stroke, neurologists should cooperate with infectious disease doctors to help patients.

Corona Virus Disease 2019: COVID-19

Severe acute respiratory syndrome coronavirus 2: SARS-CoV-2

Intensive care unit: ICU

Ethics approval and consent to participate: Ethical approval was granted by the institutional Research Ethics Committee at the Hubei Provincial hospital of Chinese tradition medicine.

Consent for publication: The written consent to publish information was obtained from this patient.

Availability of data and materials: The datasets used during the current study are available from the corresponding author on reasonable request.

Competing interests: No authors report any conflict of interest.

Funding: This work was supported by Professional Development Research Project of National Chinese Medicine Clinical Research Base of State Administration of Traditional Chinese Medicine (No. JDZX2015295) to Yanbing Ding.

Authors' contributions: Conceived the case report: Y.L. Revise the manuscript and approved the final manuscript: P. Z. and Y.D.

Acknowledgements: I would like to express my gratitude to Dr. Wu Xia for here kind help.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY et al: Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020, 395(10223):497-506.
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020:105924.
Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J: Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing. Radiology 2020:200343.
Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW et al: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020, 395(10223):514-523.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y et al: Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020.
Hoffmann S, Harms H, Ulm L, Nabavi DG, Mackert BM, Schmehl I, Jungehulsing GJ, Montaner J, Bustamante A, Hermans M et al: Stroke-induced immunodepression and dysphagia independently predict stroke-associated pneumonia - The PREDICT study. J Cereb Blood Flow Metab 2017, 37(12):3671-3682.
Regenhardt RW, Das AS, Lo EH, Caplan LR: Advances in Understanding the Pathophysiology of Lacunar Stroke: A Review. JAMA Neurol 2018, 75(10):1273-1281.
Ham PB, 3rd, Raju R: Mitochondrial function in hypoxic ischemic injury and influence of aging. Prog Neurobiol 2017, 157:92-116.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y et al: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020, 395(10223):507-513.
Backer JA, Klinkenberg D, Wallinga J: Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill 2020, 25(5).
Li S, Hafeez A, Noorulla F, Geng X, Shao G, Ren C, Lu G, Zhao H, Ding Y, Ji X: Preconditioning in neuroprotection: From hypoxia to ischemia. Prog Neurobiol 2017, 157:79-91.
Hartmann P, Schober A, Weber C: Chemokines and microRNAs in atherosclerosis. Cell Mol Life Sci 2015, 72(17):3253-3266.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL et al: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020.
Zhou Q, Yan R, Zhang Y, Li Y, Xia L: Structure of dimeric full-length human ACE2 in complex with B<sup>0</sup>AT1. 2020:2020.2002.2017.951848.
Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, Xing F, Liu J, Yip CC-Y, Poon RW-S et al: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet 2020, 395(10223):514-523.
de Wit E, van Doremalen N, Falzarano D, Munster VJ: SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016, 14(8):523-534.
Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, Jose J, Pinto R, Al-Omari A, Kharaba A et al: Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med 2018, 197(6):757-767.
Lee DT, Wing YK, Leung HC, Sung JJ, Ng YK, Yiu GC, Chen RY, Chiu HF: Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study. Clin Infect Dis 2004, 39(8):1247-1249.
Lee N, Allen Chan KC, Hui DS, Ng EK, Wu A, Chiu RW, Wong VW, Chan PK, Wong KT, Wong E et al: Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 2004, 31(4):304-309.

Download PDF

Version 1

posted

You are reading this latest preprint version

The impact of COVID-19 on ischemic stroke: A case report

Status:

Version 1

Abstract

Figures

Introduction

Case Presentation

Discussion and Conclusions

Highlight

List of Abbreviations

Declarations

References

Status:

Version 1